A detailed history of Man Group PLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Man Group PLC holds 55,022 shares of EDIT stock, worth $162,865. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,022
Previous 101,767 45.93%
Holding current value
$162,865
Previous $755,000 66.09%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.67 - $7.28 $218,299 - $340,303
-46,745 Reduced 45.93%
55,022 $256,000
Q1 2024

May 15, 2024

BUY
$7.03 - $11.07 $176,670 - $278,200
25,131 Added 32.79%
101,767 $755,000
Q4 2023

Feb 14, 2024

SELL
$6.25 - $11.11 $3.51 Million - $6.24 Million
-561,546 Reduced 87.99%
76,636 $776,000
Q3 2023

Nov 14, 2023

SELL
$6.92 - $9.31 $705,784 - $949,545
-101,992 Reduced 13.78%
638,182 $4.98 Million
Q2 2023

Aug 14, 2023

BUY
$6.36 - $11.47 $1.19 Million - $2.15 Million
187,810 Added 34.0%
740,174 $6.09 Million
Q1 2023

May 15, 2023

BUY
$7.03 - $11.53 $1.01 Million - $1.65 Million
142,984 Added 34.93%
552,364 $4 Million
Q4 2022

Feb 14, 2023

BUY
$8.32 - $13.21 $829,728 - $1.32 Million
99,727 Added 32.21%
409,380 $3.63 Million
Q3 2022

Nov 14, 2022

BUY
$12.16 - $19.42 $3.63 Million - $5.8 Million
298,655 Added 2715.54%
309,653 $3.79 Million
Q2 2022

Aug 15, 2022

BUY
$9.99 - $21.35 $109,870 - $234,807
10,998 New
10,998 $130,000
Q3 2021

Nov 15, 2021

SELL
$39.27 - $72.94 $551,390 - $1.02 Million
-14,041 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$31.29 - $56.64 $206,607 - $373,993
6,603 Added 88.77%
14,041 $796,000
Q1 2021

May 17, 2021

BUY
$39.71 - $90.58 $295,362 - $673,734
7,438 New
7,438 $313,000
Q4 2020

Feb 16, 2021

SELL
$27.07 - $84.35 $557,912 - $1.74 Million
-20,610 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$28.06 - $37.16 $980,276 - $1.3 Million
-34,935 Reduced 62.89%
20,610 $578,000
Q2 2020

Aug 14, 2020

SELL
$18.5 - $34.34 $288,563 - $535,635
-15,598 Reduced 21.92%
55,545 $1.64 Million
Q1 2020

May 15, 2020

BUY
$14.88 - $32.78 $641,967 - $1.41 Million
43,143 Added 154.08%
71,143 $1.41 Million
Q4 2019

Feb 18, 2020

BUY
$19.49 - $32.63 $50,673 - $84,838
2,600 Added 10.24%
28,000 $829,000
Q3 2019

Nov 14, 2019

SELL
$22.49 - $26.81 $870,812 - $1.04 Million
-38,720 Reduced 60.39%
25,400 $578,000
Q2 2019

Aug 14, 2019

SELL
$20.48 - $27.76 $126,976 - $172,112
-6,200 Reduced 8.82%
64,120 $1.59 Million
Q1 2019

May 15, 2019

BUY
$19.43 - $26.41 $1.37 Million - $1.86 Million
70,320 New
70,320 $1.72 Million
Q3 2018

Nov 14, 2018

SELL
$27.65 - $38.39 $242,739 - $337,025
-8,779 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$31.4 - $41.01 $3.06 Million - $3.99 Million
-97,294 Reduced 91.72%
8,779 $315,000
Q1 2018

May 15, 2018

BUY
$29.84 - $44.08 $3.17 Million - $4.68 Million
106,073 New
106,073 $3.52 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $203M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.